AxoGen Inc. (NSDQ:AXGN) said today it sold 4.8 million shares to investment firm Essex Woodlands, reeling in $17.1 million for Axogen and giving Essex Woodlands a 16% stake in the company. The funds from the sale are slated to support market growth and accelerate the company’s entry into new nerve repair markets, including the development and commercialization […]
AxoGen
Clearpath Robotics snags Intuitive Surgical design guru Hanuschik | Personnel Moves
Self-driving vehicle development company Clearpath Robotics said today it picked up Intuitive Surgical‘s (NSDQ:ISRG) director of design & management Mike Hanuschik. Hanuschik led the design and product management for Intuitive Surgical’s flagship da Vinci surgical robot system, the market leading robotic surgery platform. The da Vinci is used in over 500,000 procedures annually, according to […]
AxoGen enrolls first subject in nerve graft study
AxoGen Inc. (NSDQ:AXGN) said yesterday that it enrolled the 1st subject in a clinical trial of its Avance nerve graft. The multicenter, prospective randomized Recon study will compare the Avance graft to nerve tubes currently used for bridging peripheral nerve tissue gaps, the Florida-based regenerative medicine company said. The data from the Recon trial will […]
GI Dynamics axes medical chief Maggs | Personnel Moves
GI Dynamics (ASX:GID) said last week in a regulatory filing that it fired chief medical officer Dr. David Maggs “for cause.” The Lexington, Mass.-based medical device company did not otherwise elaborate on the reason for Maggs’s departure, which was effective June 18, according to the filing. Maggs joined GI Dynamics in April 2013 to oversee the clinical […]
Cervel Neurotech is nearing the close of an $11.9 million funding round | Medtech funding for the week of June 9, 2014
AxoGen and Brigham win $1.9M Pentagon contract for nerve repair innovation
The U.S. Dept. of Defense awarded a pair of grants worth $1.9 million to AxoGen and Brigham and Women’s Hospital in Boston in support of their efforts to develop tools to aid in peripheral nerve surgeries.
AxoGen raises $18M in support of its peripheral nerve repair products
Cordis CSO Rogers departs for HeartFlow | Personnel Moves
Campbell Rogers is leaving his post as chief scientific officer for Johnson & Johnson’s (NYSE:JNJ) Cordis Corp. – a role created for him in July 2006 – to take the chief medical officer job at startup HeartFlow.